CoChat

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts

Lorgis, Veronique, Maura, Geric, Coppa, Guillaume, Hassani, Kahina, Taillandier, Luc, Chauffert, Bruno, Apetoh, Lionel, Ladoire, Sylvain, Ghiringhelli, François · 2012 · Journal of Neuro-Oncology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy. However, to date, there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high-grade glioma. We performed a retrospective analysis of clinical factors associated with patient survival using a training cohort of 110 consecutive patients treated with bevacizumab for recurrent high-grade glioma and an independent validation cohort of 109 patients. In the training cohort, 110 consecutive patients received bevacizumab-based therapy. The number of chemotherapy cycles delivered was 1,411. Median follow-up was 12 months. Thirty-four patients (31%) had objective partial response and 24% had stable disease on magnetic resonance imaging evaluation. Median progression-free survival (PFS) and overall survival (OS) were 4.3 and 9.2 months, respectively. On univariate analysis, among classical prognosis factors, only Karnofsky status ≥70% was associated with improved outcome. Surprisingly, patients with low bevacizumab dose intensity (<5 mg/kg/week) had better PFS (12 vs. 2 months, P < 0.0001) and OS (16 vs. 6 months, P = 0.0002). On multivariate analysis, low bevacizumab dose intensity was the most significant independent prognostic factor of survival. Analysis of the validation cohort yielded similar results, externally validating this observation. This large retrospective study using two independent cohorts of high-grade glioma suggests that the currently recommended dosage of bevacizumab (5 mg/kg/week) is not optimal. Further prospective randomized trials using lower dosages are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11060-011-0748-5

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 65

Metadata

Authors
Lorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandier, L., Chauffert, B., Apetoh, L., Ladoire, S., & Ghiringhelli, F.
Affiliations
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Inserm (FR)
Corresponding author
  • Ladoire, Sylvain
  • Ghiringhelli, François
Venue
Journal of Neuro-Oncology
Published
2011-11-11
Volume
107
Issue
2
Pages
351-358
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2025106701
Cited by
60
References
29
Citations by year
2025: 5 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 3 · 2013: 2 · 2012: 2
FWCI
1.13
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Journal of Neuro-Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
bevacizumab, high-grade glioma, recurrent glioma, dose intensity, survival, prognostic factors, progression-free survival, overall survival, anti-VEGF therapy, Karnofsky performance status, dose optimization
MeSH terms
Bevacizumab, Adult, Aged, Aged, 80 and over, Brain Neoplasms, Dose-Response Relationship, Drug, Female, Glioma, Humans, Male, Middle Aged, Retrospective Studies, Reproducibility of Results, Cohort Studies, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. https://app.cochat.ai/papers/10.1007/s11060-011-0748-5
The paper
Lorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandier, L., Chauffert, B., Apetoh, L., Ladoire, S., & Ghiringhelli, F. (2012). Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-011-0748-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.